Literature DB >> 679500

'Low T3 syndrome' in patients chronically treated with an iodine-containing drug, amiodarone.

M H Jonckheer, P Blockx, I Broeckaert, C Cornette, C Beckers.   

Abstract

Cardiac patients treated with the iodine-containing drug 'amiodarone' undergo a significant iodine overload which can last for months after the drug has been withdrawn. Some patients develop hyperthyroidism and others hypothyroidism. In the hyper- or hypothyroid patients, the indices of thyroid function are modified as usually observed in these situations. In the patients remaining euthyroid while taking amiodarone or after its withdrawal, but still under its influence as shown by the iodine overload, a 'low-T3 syndrome' is observed, this state being characterized by a high total T4, a low free T4, a normal T3 resin uptake, a low total T3, a normal free T3, a high r-T3 and a relative TSH-unresponsiveness to TRH.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 679500     DOI: 10.1111/j.1365-2265.1978.tb03569.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  11 in total

1.  The effect of benziodarone on the thyroid hormone levels and the pituitary-thyroid axis.

Authors:  B Xanthopoulos; D A Koutras; M A Boukis; G D Piperingos; J Kitsopanides; A Souvatzoglou; S D Moulopoulos
Journal:  J Endocrinol Invest       Date:  1986-08       Impact factor: 4.256

2.  Effect of amiodarone on serum T4 and T3 levels in hyperthyroid patients treated with methimazole.

Authors:  O Van Reeth; C Decoster; J Unger
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

Review 3.  Euthyroid hyperthyroxinemia.

Authors:  R Rajatanavin; L E Braverman
Journal:  J Endocrinol Invest       Date:  1983-12       Impact factor: 4.256

4.  Amiodarone: the experience of the past decade.

Authors:  Y Abramovici; J Baillet; G Nguyen
Journal:  Br Med J (Clin Res Ed)       Date:  1984-01-28

5.  Serum concentrations of amiodarone during long term therapy. Relation to dose, efficacy and toxicity.

Authors:  M Stäubli; J Bircher; R L Galeazzi; H Remund; H Studer
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

6.  Treatment of amiodarone associated thyrotoxicosis by simultaneous administration of potassium perchlorate and methimazole.

Authors:  E Martino; F Aghini-Lombardi; S Mariotti; M Lenziardi; L Baschieri; L E Braverman; A Pinchera
Journal:  J Endocrinol Invest       Date:  1986-06       Impact factor: 4.256

7.  Long-term amiodarone therapy raises serum cholesterol.

Authors:  A A Lakhdar; E Farish; W S Hillis; F G Dunn
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

8.  The correlation of serum amiodarone levels with abnormalities in the metabolism of thyroxine.

Authors:  M Anastasiou-Nana; D A Koutras; G Levis; A Souvatzoglou; M A Boukis; S D Moulopoulos
Journal:  J Endocrinol Invest       Date:  1984-08       Impact factor: 4.256

9.  Amiodarone-treated patients with suppressed TSH test are at risk of thyrotoxicosis.

Authors:  M Stäubli; H Studer
Journal:  Klin Wochenschr       Date:  1985-02-15

10.  Implication from thyroid function decreasing during chemotherapy in breast cancer patients: chemosensitization role of triiodothyronine.

Authors:  Jianbo Huang; Liangbin Jin; Guangyan Ji; Lei Xing; Chaobo Xu; Xiong Xiong; Hongyuan Li; Kainan Wu; Guosheng Ren; Lingquan Kong
Journal:  BMC Cancer       Date:  2013-07-06       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.